title: Experiences with HUS in Canada: what have we learned about childhood HUS in Canada?
abstract: Experiences with childhood hemolytic uremic syndrome (HUS) in Canada will focus on the development of the Canadian Pediatric Kidney Disease Research Centre (CPKDRC) and the results of our collaborative research over a 13-year period (1985-1998).
authors.affiliation: Department of Pediatrics, University of Ottawa, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada. mclaine@travel-net.com
authors.forename: Peter N
authors.initials: PN
authors.lastname: McLaine
authors.forename: Peter C
authors.initials: PC
authors.lastname: Rowe
authors.forename: Elaine
authors.initials: E
authors.lastname: Orrbine
mesh_terms: D000293:Adolescent; D017668:Age of Onset; D002170:Canada / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D019992:Databases as Topic; D004927:Escherichia coli Infections / Q000453:epidemiology* / Q000382:microbiology*; D019453:Escherichia coli O157 / Q000378:metabolism / Q000472:pathogenicity*; D006463:Hemolytic-Uremic Syndrome / Q000453:epidemiology* / Q000382:microbiology* / Q000517:prevention & control; D006801:Humans; D007676:Kidney Failure, Chronic / Q000382:microbiology; D017646:Organosilicon Compounds / Q000627:therapeutic use; D016730:Program Development; D006435:Renal Dialysis; D012307:Risk Factors; D022603:Shiga Toxins / Q000378:metabolism; D016896:Treatment Outcome; D014312:Trisaccharides / Q000627:therapeutic use
chemical_list: D017646:Organosilicon Compounds; C119238:SYNSORB Pk; D022603:Shiga Toxins; D014312:Trisaccharides